Kirk N Garratt1, W Douglas Weaver2, Ronald G Jenkins2, Thomas K Pow2, Laura Mauri2, Dean J Kereiakes2, Kenneth J Winters2, Thomas Christen2, Dominic J Allocco2, David P Lee2. 1. From Lenox Hill Hospital, New York, NY (K.N.G.); Henry Ford Heart and Vascular Institute, Henry Ford Health System, Detroit, MI (W.D.W.); Kootenai Medical Center, Coeur d'Alene, ID (R.G.J.); Lakeland Hospitals at St. Joseph, St. Joseph, MI (T.K.P.); Brigham and Women's Hospital, Boston, MA (L.M.); The Christ Hospital Heart and Vascular Center/The Lindner Research Center Heart & Vascular Center, Cincinnati, OH (D.J.K.); Eli Lilly and Co, Indianapolis, IN (K.J.W.); Boston Scientific Corporation, Marlborough, MA (T.C., D.J.A.); and Stanford University Medical Center, Stanford, CA (D.P.L.). kgarratt@lenoxhill.net. 2. From Lenox Hill Hospital, New York, NY (K.N.G.); Henry Ford Heart and Vascular Institute, Henry Ford Health System, Detroit, MI (W.D.W.); Kootenai Medical Center, Coeur d'Alene, ID (R.G.J.); Lakeland Hospitals at St. Joseph, St. Joseph, MI (T.K.P.); Brigham and Women's Hospital, Boston, MA (L.M.); The Christ Hospital Heart and Vascular Center/The Lindner Research Center Heart & Vascular Center, Cincinnati, OH (D.J.K.); Eli Lilly and Co, Indianapolis, IN (K.J.W.); Boston Scientific Corporation, Marlborough, MA (T.C., D.J.A.); and Stanford University Medical Center, Stanford, CA (D.P.L.).
Abstract
BACKGROUND: The TAXUS Liberté Post Approval Study (TL-PAS) contributed patients treated with TAXUS Liberté paclitaxel-eluting stent and prasugrel to the Dual Antiplatelet Therapy Study (DAPT) that compared 12 and 30 months thienopyridine plus aspirin therapy after drug-eluting stents. METHODS AND RESULTS: Outcomes for 2191 TL-PAS patients enrolled intoDAPT were assessed. The DAPT coprimary composite end point (death, myocardial infarction [MI], or stroke) was lower with 30 compared with 12 months prasugrel treatment (3.7% versus 8.8%; hazard ratio [HR], 0.407; P<0.001). Rates of death and stroke were similar between groups, but MI was significantly reduced with prolonged prasugrel treatment (1.9% versus 7.1%; HR, 0.255; P<0.001). The DAPT coprimary end point, stent thrombosis, was also lower with longer therapy (0.2% versus 2.9%; HR, 0.063; P<0.001). MI related to stent thrombosis (0% versus 2.6%; P<0.001) and occurring spontaneously (1.9% versus 4.5%; HR, 0.407; P=0.007) were both reduced with prolonged prasugrel. MI rates increased within 90 days of prasugrel cessation after both 12 and 30 months treatment. Composite Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) moderate or severe bleeds were modestly increased (2.4% versus 1.7%; HR, 1.438; P=0.234) but severe bleeds were not more frequent (0.3% versus 0.5%; HR, 0.549; P=0.471) in the prolonged treatment group. CONCLUSIONS:Prasugrel and aspirin continued for 30 months reduced ischemic events for the TAXUS Liberté paclitaxel-eluting stent patient subset from DAPT through reductions in MI and stent thrombosis. Withdrawal of prasugrel was followed by an increase in MI after both 12 and 30 months therapy. The optimal duration of dual antiplatelet therapy with prasugrel after TAXUS Liberté paclitaxel-eluting stent remains unknown, but appears to be >30 months. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00997503.
RCT Entities:
BACKGROUND: The TAXUS Liberté Post Approval Study (TL-PAS) contributed patients treated with TAXUS Liberté paclitaxel-eluting stent and prasugrel to the Dual Antiplatelet Therapy Study (DAPT) that compared 12 and 30 months thienopyridine plus aspirin therapy after drug-eluting stents. METHODS AND RESULTS: Outcomes for 2191 TL-PASpatients enrolled into DAPT were assessed. The DAPT coprimary composite end point (death, myocardial infarction [MI], or stroke) was lower with 30 compared with 12 months prasugrel treatment (3.7% versus 8.8%; hazard ratio [HR], 0.407; P<0.001). Rates of death and stroke were similar between groups, but MI was significantly reduced with prolonged prasugrel treatment (1.9% versus 7.1%; HR, 0.255; P<0.001). The DAPT coprimary end point, stent thrombosis, was also lower with longer therapy (0.2% versus 2.9%; HR, 0.063; P<0.001). MI related to stent thrombosis (0% versus 2.6%; P<0.001) and occurring spontaneously (1.9% versus 4.5%; HR, 0.407; P=0.007) were both reduced with prolonged prasugrel. MI rates increased within 90 days of prasugrel cessation after both 12 and 30 months treatment. Composite Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) moderate or severe bleeds were modestly increased (2.4% versus 1.7%; HR, 1.438; P=0.234) but severe bleeds were not more frequent (0.3% versus 0.5%; HR, 0.549; P=0.471) in the prolonged treatment group. CONCLUSIONS:Prasugrel and aspirin continued for 30 months reduced ischemic events for the TAXUS Liberté paclitaxel-eluting stent patient subset from DAPT through reductions in MI and stent thrombosis. Withdrawal of prasugrel was followed by an increase in MI after both 12 and 30 months therapy. The optimal duration of dual antiplatelet therapy with prasugrel after TAXUS Liberté paclitaxel-eluting stent remains unknown, but appears to be >30 months. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00997503.
Authors: Robert W Yeh; Dean J Kereiakes; Philippe Gabriel Steg; Stephan Windecker; Michael J Rinaldi; Anthony H Gershlick; Donald E Cutlip; David J Cohen; Jean-Francois Tanguay; Alice Jacobs; Stephen D Wiviott; Joseph M Massaro; Adrian C Iancu; Laura Mauri Journal: J Am Coll Cardiol Date: 2015-03-15 Impact factor: 24.094
Authors: Jacek Kubica; Piotr Adamski; Piotr Niezgoda; Dimitrios Alexopoulos; Jolita Badarienė; Andrzej Budaj; Katarzyna Buszko; Dariusz Dudek; Tomasz Fabiszak; Mariusz Gąsior; Robert Gil; Diana A Gorog; Stefan Grajek; Paul A Gurbel; Marcin Gruchała; Miłosz J Jaguszewski; Stefan James; Young-Hoon Jeong; Bernd Jilma; Jarosław D Kasprzak; Andrzej Kleinrok; Aldona Kubica; Wiktor Kuliczkowski; Jacek Legutko; Maciej Lesiak; Jolanta M Siller-Matula; Klaudiusz Nadolny; Krzysztof Pstrągowski; Salvatore Di Somma; Giuseppe Specchia; Janina Stępińska; Udaya S Tantry; Agnieszka Tycińska; Monica Verdoia; Wojciech Wojakowski; Eliano P Navarese Journal: Cardiol J Date: 2020-10-19 Impact factor: 2.737
Authors: Ada C Stefanescu Schmidt; Dean J Kereiakes; Donald E Cutlip; Robert W Yeh; Ralph B D'Agostino; Joseph M Massaro; Wen-Hua Hsieh; Laura Mauri Journal: Circulation Date: 2017-02-22 Impact factor: 29.690
Authors: Arun K Thukkani; Kush Agrawal; Lillian Prince; Kyle J Smoot; Alyssa B Dufour; Kelly Cho; David R Gagnon; Galina Sokolovskaya; Samantha Ly; Sara Temiyasathit; David P Faxon; J Michael Gaziano; Scott Kinlay Journal: J Am Coll Cardiol Date: 2015-09-08 Impact factor: 24.094